24 April 2025
24 April 2025
The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug developers.
The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.
AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.
Veraxa Biotech will gain access to $253m in cash from Voyager to advance its cancer drug pipeline.
Repertoire will obtain an upfront payment of $35m from Genentech, with the potential for up to $730m in additional milestones.
In a trial, patients showed neurological improvement when treated with the therapy versus a placebo.
The agreement facilitates EditCo to not only offer genomic knock-ins but also functional validation services.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
